Hamlet BioPharma Participates in Økonomisk Ugebrev’s Life Science Investor Konference 2024

Hamlet Biopharma
|
October 8, 2025

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, participated in Økonomisk Ugebrev’s Life Science Investor Konference held in Copenhagen on November 27th 2024. Økonomisk Ugebrev, serves as a platform for collaboration and investment opportunities. Hamlet BioPharma presented the advances made by the company to a diverse audience and the presentation was followed by lively discussions.

The video from the event is now available on Hamlet BioPharma’s web site:

https://hamletbiopharma.com/news/media-archive/

For more information about Økonomisk Ugebrev, please visit Ugebrev’s official website.

For further information, please contact:

Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46-709 42 65 49

catharina.svanborg@hamletpharma.com

Martin Erixon, CEO Hamlet BioPharma, +46-733 00 43 77

martin.erixon@hamletpharma.com

Related Documents
Recent posts
An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.
Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958
Subscribe to receive newsletters
© 2025
Hamlet BioPharma.